Fujitsu Siemens computers has launched the ESPRIMO MA, a mobile tablet PC for the health sector. The new device, which weighs 1.3kg and claims battery life of up to four hours, is based on the Intel Mobile Clinical Assistant platform and will be available in the second quarter of 2009. Specifically designed for use on hospital wards, or visiting patients in their homes, the ESPRIMO MA rugged wireless tablet PC is able to update data via an integrated barcode and RFID reader. The ESPRIMO MA features a fully sealed housing and can be completely sterilised for use in healthcare environments. Fujitsu Siemens claim the device, which as well as being sealed, is fan less and passively cooled, is the only one on the market that can be used in sterile environments, including operating rooms. Additional features include 3G and wireless LAN, which enables electronic patient data to be accessed and recorded at the point of care, and a dual smartcard reader, which enables secure authentication of healthcare professionals. According to Fujitsu Siemens the ESPRIMO MA meets all of the standards set by Germany’s gematik health IT agency covering future use of the German electronic health smartcard for identifying and authenticating GPs and emergency services. To integrate the ESPIMO MA into clinics and hospitals, Fujitsu Siemens, and its partner Intel, are working with a range of clinical software vendors to ensure full compatibility with the new device and the MCA platform it is based on. “Many modern clinics have already recognised that a specialist mobility strategy is increasingly important to maximise the efficiency of processes and for patient well-being. As a result, demand for mobile PCs in the healthcare sector is at an all time high,” said Armin Kumpf, senior director business mobile at Fujitsu Siemens Computers. Pricing has not been announced but is expected to be in line with a high end business notebook.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.